Stock ARQT ARCUTIS BIOTHERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Arcutis Biotherapeutics, Inc.

Equities

ARQT

US03969K1088

Market Closed - Nasdaq
Other stock markets
 04:00:08 2024-05-17 pm EDT 		5-day change 1st Jan Change
9.18 USD +0.60% Intraday chart for Arcutis Biotherapeutics, Inc. +17.09% +184.21%
May. 15 Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating MT
May. 15 Sector Update: Health Care Stocks Rise Pre-Bell Wednesday MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating
MT
Sector Update: Health Care Stocks Rise Pre-Bell Wednesday
MT
Sector Update: Health Care
MT
Mizuho Securities Adjusts Arcutis Biotherapeutics Price Target to $18 From $17, Maintains Buy Rating
MT
Arcutis Biotherapeutics Q1 Loss Narrows as Revenue Surges; Shares Soar Premarket
MT
Arcutis Biotherapeutics Q1 Loss Narrows, Revenue Increases; Shares Jump
MT
Transcript : Arcutis Biotherapeutics, Inc., Q1 2024 Earnings Call, May 14, 2024
Arcutis Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Earnings Flash (ARQT) ARCUTIS BIOTHERAPEUTICS Posts Q1 Revenue $49.6M
MT
Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update
GL
Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology
GL
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
GL
Arcutis Appoints David Topper as Chief Financial Officer
GL
Arcutis Biotherapeutics, Inc. Announces Chief Financial Officer Changes
CI
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
AQ
Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference
AQ
Arcutis Biotherapeutics, Inc.(NasdaqGS:ARQT) added to S&P Biotechnology Select Industry Index
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ARQT Stock
  4. News Arcutis Biotherapeutics, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW